GLENN CUNNINGHAM to Prostate-Specific Antigen
This is a "connection" page, showing publications GLENN CUNNINGHAM has written about Prostate-Specific Antigen.
Connection Strength
0.970
-
Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. J Clin Endocrinol Metab. 2019 12 01; 104(12):6238-6246.
Score: 0.606
-
Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003 May-Jun; 24(3):299-311.
Score: 0.192
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.
Score: 0.050
-
In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor. Prostate. 2003 Sep 15; 57(1):1-7.
Score: 0.049
-
Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017 Feb; 119(2):216-224.
Score: 0.030
-
Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016 Feb 18; 374(7):611-24.
Score: 0.029
-
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004 May; 89(5):2085-98.
Score: 0.013